Research + insights
Explore the following resources on medication-assisted treatment, including original research that Ophelia has published in leading scientific journals. We're always looking for better ways to care for patients, and we're committed to sharing this knowledge with the world.


We conducted a study and found that almost 3/4 of Ophelia patients who had in-network insurance stayed in treatment for more than six months. Read article here.
Read more
Remote urine drug testing can be successfully adapted to exclusively virtual telehealth settings. Ophelia provides real-time, face-to-face high-quality care adherent to in-person best practices.
Read more
Telehealth for OUD holds promise to rapidly scale high quality accessible care for individuals affected by the opioid crisis.
Read morePartner with Ophelia to improve access and drive clinical outcomes

85% of Ophelia patients are engaged in treatment early in care (HEDIS measure: Engagement of Alcohol or Other Drug Treatment measure), more than 5x national average

79% of Ophelia patients are retained in treatment at 180 days (HEDIS measure: Pharmacotherapy for Opioid Use Disorder), more than 2x national average

Ophelia earns a Net Promoter Score (NPS) of 97 among patients, 3x the industry average